1, and good shares (12.34 +0.33%, diagnosis)
In the field of health care services to test the PPP model for many years, recently announced a successive announcement of the third people's hospital in Henan Yushi County, Guizhou Pingtang County Bureau of Health Bureau, to carry out medical construction services.
Hejia shares and Guizhou Pingtang County cooperation projects with a total investment of up to 2.9 billion yuan for the company's future development. Hejia is a pioneer in the transformation of medical device companies into the medical service industry, especially in the fine molecule areas of hemodialysis, rehabilitation and medical informatization highlights.
2, Yibai Pharmaceuticals (15.40 +0.13%, diagnosis)
As a leading anti-tumor drug enterprise, in recent years, actively to the oncology medical service industry transformation. 2016 April, the company's subordinate Anhui Province oncology doctor group was formally established,
has acquired a tertiary level B hospitals, signing up for 11 non-equity relationship with the oncology treatment center, 8 In the future, it will develop according to the model of a large physician enterprise group. Medical service is expected to become an important performance growth point of the company in the future.
3, Yueyue medical (22.93 +2.92%, diagnosis)
It is the largest rehabilitation care, medical oxygen and medical clinical series of medical equipment specialized production enterprises, our country's leading enterprises in the medical equipment industry. It produces more than 50 varieties of products, which is one of the most abundant product varieties among domestic manufacturers in the same industry.
According to the company's official website, at present, the company's oxygen concentrator, nebulizer, blood pressure monitor, stethoscope, ultra-slight oxygen valve five products of the market share of the domestic first, of which the oxygen concentrator product is to reach the level of global sales of the first.
Wheelchair carts and electronic blood pressure monitors have the second largest market share in China. In addition, the company also actively enter the Internet medical, to create a cloud health platform for chronic disease management. The company's perfect product and industrial layout, is expected to fully benefit from the outbreak of the elderly medical market.
4, Beida Medicine
The acquisition of Beida Medicine completed the business expansion. The company in 2011 to the Beida International Hospital Group directional hair acquisition to buy 100% of the equity of Beida Medicine. North Medicine and its subsidiaries from 2011 into the company's statements. The company added into the drug, medical equipment sales and distribution business, the pharmaceutical industry chain is further extended.
5, Jinling Pharmaceutical
Three-party cooperation to run a medical sample, policy support for private capital to run a medical model. We believe that the company's value is centered on hospital assets. We believe that Suqian hospital more important role is to enhance the company's valuation. The current direction of health care reform, pharmaceutical companies are always subject to the risk of downward price impact on gross margins, while medical institutions are completely free of that concern.
Hospitals are always in the strongest position in the entire pharmaceutical system, the policy risk is much smaller compared to the pharmaceutical companies, the quality of the operation is sufficient to protect. At the same time, the company and the acquisition of Yizheng Hospital in July 2012, indicating the company's expansion plans in medical services.
When the company's medical services account for a larger and larger share of profits, it is expected to usher in a double boost in performance and valuation. And, once the future success of the promotion of three A, the hospital's profitability is expected to be further enhanced.
6, Huabang health
Focusing on medicine, to build a large Huabang medical alliance. The company's medical health business planning is mainly divided into two categories: national projects, including rehabilitation and tourism health care, Internet + skin disease detection medical center; regional projects, Huabang Medical Industrial Park and participation in the restructuring of public hospitals.
First of all, with the advantages of the dermatology field to create a professional medical platform. The company's dermatology drugs national market share of about 10%, covering more than 80% of skin hospitals and departments, has accumulated a large number of dermatological medical resources and patient groups, and authoritative academic institutions, medical experts to establish a good cooperation, through equity cooperation and other forms of national medical services layout.
At the same time, the company will also build a dermatology Internet medical platform, connecting doctors and patients for health counseling and online diagnosis and treatment, as well as the development of drug supply channels, forming an OTO ecological closed loop.